Stats by Source
Global, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Global = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Global can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Global | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 267 | 26 | 230 |
| Samples | 140 | 19 | 115 |
| Peptides | 106 | 13 | 92 |
Function
GCG · Glucagon
The protein encoded by this gene is a proglucagon precursor that is cleaved into four distinct mature peptides. One of these, glucagon, is a pancreatic hormone that counteracts the glucose-lowering action of insulin by stimulating glycogenolysis and gluconeogenesis in the liver. In addition, glucagon promotes lipolysis and ketone body formation during prolonged fasting or stress. Glucagon secretion is stimulated by low blood glucose and inhibited by high glucose or insulin. Glucagon is a ligand for a specific G-protein linked receptor called glucagon receptor, which activates the Gs protein-adenylate cyclase-cAMP-protein kinase A signaling pathway to regulate carbohydrate and lipid metabolism. Two of the other peptides, glucagon-like peptide-1 and glucagon-like peptide-2, are produced by the intestinal L-cells and secreted in response to nutrient ingestion, where they function as important regulators of glucose metabolism and intestinal physiology. Glucagon-like peptide-1 enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety, making it a key incretin hormone for maintaining postprandial glucose levels. Glucagon-like peptide-2 primarily acts on the gut, promoting intestinal growth, enhancing nutrient absorption, and supporting mucosal integrity. Both peptides exert their effects through specific G-protein-coupled receptors, glucagon-like peptide-1 receptor and glucagon-like peptide-2 receptor, respectively, and analogs of glucagon-like peptide-1 are used clinically for the treatment of type 2 diabetes and obesity. The fourth peptide is similar to glicentin, an active enteroglucagon produced in the intestinal L-cells. This peptide is thought to have multiple roles in gastrointestinal physiology, including stimulating intestinal growth, modulating gut motility, and influencing the secretion of other gut hormones. Although its precise functions are less well-characterized than those of glucagon, glucagon-like peptide-1, or glucagon-like peptide-2, glicentin-like peptides may contribute to postprandial digestive processes and the coordination of nutrient absorption. [provided by RefSeq, Mar 2026].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
Top recurrent amino-acid changes along the protein · needle height = number of mutations
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation Distribution
Where GCG is mutated · all tissues, split by cell line vs tissue
How many mutations in GCG were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 13 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 267 mutations in GCG
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Peptide |
|---|